Background: Although differential expression of retinoic acid receptor (RAR) subtypes between benign and malignant thyroid tissues has been described, their diagnostic value has not been reported. Aim: To investigate the diagnostic accuracy of RAR and retinoid X receptor (RXR) subtype protein expression for the differential diagnosis of thyroid neoplasms. Methods: We used a tissue array containing 93 benign thyroid tissues (normal thyroid, multinodular goiter, and follicular adenoma (FA)) and 77 thyroid carcinomas (papillary thyroid carcinoma (PTC), follicular thyroid carcinoma, and follicular variant of PTC (FVPTC)). Immunostaining was done for RAR and RXR subtypes. Staining was analyzed semiquantitatively based on receiver operating curve analyses and using hierarchical cluster analysis. Results: We found increased expression of cytoplasmic (c) RARA, cRARG, cRXRB and decreased expression of nuclear (n) RARB, nRARG, and nRXRA in thyroid carcinomas compared with benign tissues. We found three proteins differently expressed between FA and FTC and five proteins differentially expressed between FA and FVPTC, with high diagnostic accuracies. Using cluster analysis, the combination of negative staining of membranous RXRB and positive staining for cRXRB had a high positive predictive value (98%) for malignant thyroid disease, whereas the combination of positive nRXRA and negative cRXRB staining had a high predictive value (91%) for benign thyroid lesions. Conclusion: We conclude that differences in RAR and RXR subtype protein expression may be valuable for the differential diagnosis of thyroid neoplasms. The results of this study and especially the value of cluster analysis have to be confirmed in subsequent studies.
Introduction
The microscopical distinction between benign and malignant neoplastic thyroid nodules by conventional histology is often difficult as these lesions may share overlapping histological characteristics. Therefore, it is important to identify new markers to distinguish benign from malignant thyroid tumors. In recent years, several immunohistochemical markers have been studied to improve the differential diagnosis of thyroid lesions, using both candidate markers and unbiased approaches (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) .
The expression of retinoid receptors may be interesting for the differentiation between benign and malignant thyroid tissues. Retinoids are important for growth, differentiation, and morphogenesis in vertebrates (13) . Retinoids are derivatives of vitamin A (i.e. retinol). Retinoid receptors belong to the family of nuclear receptors and can be distinguished in retinoic acid receptors (RAR) and retinoid X receptors (RXR). According to the literature, retinoid receptors appear to be differentially expressed in benign and malignant thyroid tissues, the general picture being decreased expression of retinoid receptor subtypes in thyroid cancer (Table 1) (14) (15) (16) (17) (18) (19) (20) , which may also have therapeutic implications (17, 18, (21) (22) (23) . However, in these publications on retinoid receptor expression in thyroid lesions, the question whether retinoid receptor expression could be used for the differential diagnosis of thyroid neoplasms was not addressed, probably because most studies included relatively small number of patient samples or the studies included only a subset of retinoid receptors (Table 1) .
We, therefore, decided to study the diagnostic value of RAR and RXR subtype expression in benign and malignant thyroid tissues, using receiver operating curve (ROC) analyses as well as hierarchical cluster analysis (12) . In addition, we also studied the prognostic value of RAR expression for relapse-free survival. 
Tissue microarray
Formalin-fixed, paraffin-embedded blocks routinely prepared from surgical specimens of thyroid tumors were selected for this study. Representative areas containing tumor or adjacent normal tissue were identified by a pathologist. Triplicate tissue cores with a diameter of 0.6 mm were taken from each specimen (Beecher Instruments, Silver Springs, MD, USA) and arrayed on a recipient paraffin block, using standard procedures (24) .
Immunohistochemistry methods
Four micrometer consecutive tissue sections were cut from each arrayed paraffin block and prepared on pathological slides. The sections were deparaffinized in xylene followed by 0.3% hydrogen peroxide in methanol at room temperature for 20 min to block endogenous peroxidase.
After rehydration, antigen retrieval was performed by microwave treatment in 0.001 M citrate buffer (pH 6.0). The sections were incubated with the following primary antibodies against RAR and RXR subtypes: anti-RARA monoclonal antibody 9A9A6, dilution 1:3000; anti-RARB monoclonal antibody 8B10B2, dilution 1:200; anti-RARG monoclonal antibody. 4G-7A11, dilution 1:350; anti-RXRA monoclonal antibody 4RX3A2, dilution 1:1000 (all gifts of Dr C Rochette-Egly, IGBMC, Illkirch, France), anti-RXRB polyclonal antibody sc-831, dilution 1:650 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-RXRG polyclonal antibody sc-555, dilution 1:500 (Santa Cruz). Sections were incubated overnight at room temperature with the primary antibodies, dissolved in PBS with 1% bovine serum albumin. Subsequently, the sections were incubated for 30 min with either the biotinylated rabbit-anti-mouse conjugate, dilution 1:200 or goat-anti-rabbit, dilution 1:400 (DakoCytomation, Glostrup, Denmark), followed by incubation for 30 min with the streptavidin-biotin-peroxidase conjugate. This step was performed by 10-min incubation with 3,3 0 -diaminobenzidinetetrachloride substrate in a buffered 0.05-M Tris/HCl (pH 7.6) solution containing 0.002% hydrogen peroxide. Negative controls were stained with the primary antibody omitted. The sections were counterstained with hematoxylin.
Immunohistochemical scoring
A semiquantitative assessment of immunohistochemical scoring was performed including both the intensity of staining and the percentage of positive cells. The percentage of cells with positive staining was scored as follows: O0-20%: '1', O20-50%: '2', O50-70%: '3', and O70-100% '4'. The staining intensity was scored as faint: '1', intermediate: '2', and intense: '3'. Scores for proportion of positive cells and intensity were multiplied. Nuclear, cytoplasmic, and membranous staining was scored independently. The total score per sample therefore ranged from 0 to 12. Score results for triplicate samples were averaged. 
Results

RAR and RXR expression in thyroid lesions: benign versus malignant
The scores for expression of RAR and RXR receptor subclasses are shown in Table 2 . Benign tissue samples had an overall lower expression of cytoplasmic RARA (cRARA), cytoplasmic RARG (cRARG), and cytoplasmic RXRB (cRXRB) and a higher expression of nuclear RARA (nRARA), nuclear (n) RARB, nuclear RARG (nRARG) and nuclear RXRA (nRXRA) compared with malignant tissues. FA scored particularly high for nuclear RXRA (nRXRA) and low for nuclear RXRB (nRXRB) expression. FVPTC also had a very low expression of nRXRB. RXRG staining did not reveal a positive result in all thyroid tissues, and was excluded from further analyses. Figure 1 shows the differences in expression patterns for different categories of thyroid tissues. All RAR and RXR subtypes appeared to be differentially expressed between malignant thyroid lesions and normal thyroid tissue.
RAR and RXR expression in thyroid lesions: follicular lesions
The differentiation between follicular lesions (FA, FTC, and FVPTC) is difficult. Therefore, we compared these subgroups separately. FTC had a significantly lower expression of nRARB, nRXRA, and mRXRB compared with FA. FVPTC had a significantly lower expression of nRARA, nRARB, nRARG, nRXRA, and mRXRB compared with FA (Fig. 1) . 
ROC analyses
For each differentially expressed antibody between two categories, the optimal cut-off values for the distinction between the two histological classes were determined by ROC analysis. Only antibodies with sensitivities and specificities above 70% were used for further analyses (Table 3) . Comparison of the expression between benign and malignant thyroid tissues revealed sensitivities and specificities O70% for nRXRA, cRXRB, and mRXRB, the highest sensitivity (89%) and specificity (96%) for nuclear RXRA (Table 3) . NRXRA and cRXRB also discriminated reasonably between malignant and normal thyroid tissues.
In the comparison between FA and FTC, nRARB, nRARA, cRXRB, and mRXRB had sensitivities and specificities above 70%, the highest sensitivity for FTC found for nRARA (85%) and the highest specificity for nRARB (91%; Table 3 ).
In the comparison between FA and FVPTC, nRARB, nRARG, nRARA, nRXRA and mRXRB had sensitivities and specificities above 70%. The highest sensitivity for FVPTC was found for nRXRA (100%) and the highest specificities for both nuclear nRARA (91%) and nRARG (91%; Table 3 ).
Hierarchical cluster analysis
To identify the optimal combinations of RAR and RXR subtype expression for the differential diagnosis of thyroid neoplasms, we performed an unsupervised hierarchical cluster analysis, the results of which are shown in Fig. 2 and Table 4 . We found that 98% of thyroid lesions in cluster 2 (negative staining of mRXRB and positive staining for cRXRB) were malignant, whereas 91% of the lesions in cluster 4 (positive staining for nRXRA and a negative staining for cRXRB) were benign. The diagnostic parameters are summarized in Table 4 .
In general, the follicular lesions did not cluster separately, but we found that only one FA was present in cluster 2 (high positive predictive value for malignancy), whereas in cluster 4 (high positive predictive value for benign lesions) only one FTC was present (Fig. 3) .
Discussion
The present study was performed to evaluate the diagnostic value of the expression of RAR and RXR subtypes in a large panel of thyroid neoplasms. To our knowledge, the diagnostic value of RAR and RXR receptor expression for the differential diagnosis of thyroid neoplasms has not been published before (14) (15) (16) (17) (18) (19) (20) . Our study also differed from earlier ones with regard to the identification of optimal semiquantitative cut-off levels using ROC analyses and hierarchical cluster analysis.
In general, we found an increased expression of cRARA, cRARG, cRXRB, and a decreased expression of nRARB, nRARG, and nRARA in thyroid carcinomas compared with benign thyroid tissue. The most challenging pathological differential diagnosis is between FA, FTC, and FVPTC. We found three proteins differentially expressed between FA and FTC and five proteins differentially expressed between FA and FVPTC. In the comparison between FA and FTC the highest sensitivity for FTC was found for nRARA and the highest specificity for nRARB. In the comparison between FA and FVPTC, the highest sensitivity for FVPTC was found for nRXRA and the highest specificities for nRARA and nRARG. Table 3 Diagnostic value of RAR and RXR differentially expressed in thyroid tissues with sensitivity and specificity above 70%.
Malignant versus benign Malignant versus normal
Cut-off level MNG5  MNG1  FTC6  FTC5  FVPTC10  FVPTC8  FVPTC7  FVPTC6  FVPTC5  FVPTC3  FVPTC2  FVPTC1  PTC47   PTC17  PTC4  PTC3  FA12  FA5  CTL63  CTL62  CTL57  CTL47  CTL46  CTL42  CTL41  CTL37  CTL35  CTL33  CTL32  CTL28  CTL23  CTL21  CTL20  CTL17  CTL16  CTL15  CTL13  CTL12  CTL10  CTL7  CTL1  MNG16  MNG9 (18) . There are two studies on RXRB expression in thyroid neoplasms (15, 16) . They both found decreased or absent expression of RXRB in carcinomas. One of these studies, however, (15) used RT-PCR and contained only 12 human thyroid carcinoma samples. In our study, we differentiated between nuclear, cytoplasmic, and membranous staining. The only study that also differentiated between nuclear and cytoplasm staining pattern, only investigated RXR isoform expression (16) .
We performed a cluster analysis including all studied tissues and antibodies. Our findings showed that the combination of negative staining of mRXRB and a positive staining for cRXRB had a high accuracy for the detection of malignant thyroid tissues, whereas the combination of a positive staining for nRXRA and a negative staining for cRXRB was present in most benign tissues.
There are some limitations to our study. Although, we were able to distinguish between follicular lesions, the number of follicular lesions was relatively small. Therefore, additional studies should be performed with larger numbers of follicular lesions, also including histological subtypes of follicular lesions. Moreover, the findings of our study and the clinical usefulness of hierarchical cluster analysis have to be validated in subsequent studies and most importantly in cytological preparations. Also, other difficult-to-classify thyroid neoplasms such as minimally invasive follicular carcinomas as well as FA subclasses should be included in subsequent studies. The biological mechanisms responsible for the differential expression of RAR and RXR between thyroid tissues also remain to be elucidated. In conclusion, differences in RAR and RXR subtype protein expression as studied by immunohistochemistry may be of additional value in the differential diagnosis of thyroid neoplasms.
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